About Pfenex (NYSEAMERICAN:PFNX)
Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-2.86516853932584
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-63.57%
Return on Assets-46.31%
Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions
What is Pfenex's stock symbol?
Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."
How were Pfenex's earnings last quarter?
Pfenex Inc (NYSEAMERICAN:PFNX) issued its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.17. The biotechnology company had revenue of $5.02 million for the quarter, compared to the consensus estimate of $3.30 million. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. The company's revenue was down 89.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.46 earnings per share. View Pfenex's Earnings History.
When will Pfenex make its next earnings announcement?
Where is Pfenex's stock going? Where will Pfenex's stock price be in 2018?
2 brokers have issued 12 month target prices for Pfenex's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Pfenex's share price to reach $8.00 in the next year. View Analyst Ratings for Pfenex.
Who are some of Pfenex's key competitors?
Some companies that are related to Pfenex include Ampio Pharmaceuticals (AMPE), ImmuPharma (IMM), Verona Pharma (VRP), Dimension Therapeutics (DMTX), Summit Therapeutics (SUMM), Motif Bio (MTFB), Ergomed (ERGO), Nexvet Biopharma (NVET), OncoCyte (OCX), Rexahn Pharmaceuticals (RNN), OptiBiotix Health (OPTI), Synthetic Biologics (SYN), Biopharmx (BPMX), ANGLE (AGL), Actinium Pharmaceuticals (ATNM), Avacta Group (AVCT), Shield Therapeutics (STX) and ValiRx (VAL).
Who are Pfenex's key executives?
Pfenex's management team includes the folowing people:
- Evert B. Schimmelpennink, President, Chief Executive Officer, Acting Principal Financial Officer, Secretary, Director (Age 45)
- Susan A. Knudson, Chief Financial Officer, Principal Financial Officer (Age 53)
- Patricia Lady CPA, Chief Accounting Officer (Age 58)
- Hubert C. Chen M.D., Chief Medical Officer (Age 48)
- Patrick K. Lucy, Chief Business Officer (Age 49)
- Robin D. Campbell Ph.D., Independent Director (Age 62)
- Dennis M. Fenton Ph.D., Independent Director (Age 65)
- Phillip M. Schneider, Independent Director (Age 60)
- John M. Taylor III, Independent Director (Age 52)
Has Pfenex been receiving favorable news coverage?
News stories about PFNX stock have been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pfenex earned a daily sentiment score of 0.20 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 44.52 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Pfenex's major shareholders?
Pfenex's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (11.82%),
SANDERS MORRIS HARRIS LLC
SANDERS MORRIS HARRIS LLC
(6.94%), Sanders Morris Harris LLC (5.75%), Renaissance Technologies LLC (4.29%) and Perceptive Advisors LLC (2.21%). Company insiders that own Pfenex stock include Jason Grenfell-Gardner, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.
Which major investors are selling Pfenex stock?
Which major investors are buying Pfenex stock?
PFNX stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Mackenzie Financial Corp, Renaissance Technologies LLC, Millennium Management LLC, Spark Investment Management LLC, Franklin Resources Inc. and Deutsche Bank AG. View Insider Buying and Selling for Pfenex.
How do I buy shares of Pfenex?
Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pfenex's stock price today?
One share of PFNX stock can currently be purchased for approximately $5.10.
How big of a company is Pfenex?
Pfenex has a market capitalization of $106.11 million.
How can I contact Pfenex?
Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.
MarketBeat Community Rating for Pfenex (PFNX)MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pfenex (NYSEAMERICAN:PFNX) Earnings History and Estimates Chart
Pfenex (NYSEAMERICAN PFNX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q3 2017||($0.54)||($0.37)||$3.30 million||$5.02 million||View||N/A|
|8/9/2017||Q2 2017||($0.46)||($0.52)||$3.10 million||$3.03 million||View||Listen|
|5/8/2017||Q1 2017||($0.57)||($0.43)||$2.50 million||$2.80 million||View||Listen|
|3/15/2017||Q4 2016||($0.66)||($0.45)||$2.50 million||$5.47 million||View||N/A|
|11/9/2016||Q316||($0.56)||$1.46||$3.18 million||$48.82 million||View||Listen|
|8/8/2016||Q216||($0.47)||($0.43)||$2.55 million||$3.10 million||View||N/A|
|5/9/2016||Q116||($0.45)||($0.35)||$2.35 million||$2.76 million||View||N/A|
|3/10/2016||Q415||($0.59)||($0.37)||$2.56 million||$3.30 million||View||Listen|
|11/13/2015||Q315||($0.46)||($0.33)||$2.05 million||$2.06 million||View||Listen|
|8/13/2015||Q215||($0.39)||($0.27)||$2.07 million||$2.30 million||View||Listen|
|5/14/2015||Q115||($0.24)||($0.29)||$2.10 million||$2.00 million||View||Listen|
|3/16/2015||Q4||($0.20)||($0.18)||$2.05 million||$2.02 million||View||N/A|
|11/13/2014||Q3||($0.25)||($0.16)||$2.13 million||$2.80 million||View||N/A|
|8/29/2014||($0.15)||($1.67)||$1.75 million||$3.27 million||View||N/A|
Pfenex (NYSEAMERICAN:PFNX) Earnings Estimates
2019 EPS Consensus Estimate: ($1.53)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Pfenex (NYSEAMERICAN:PFNX)
No dividend announcements for this company have been tracked by MarketBeat.com
Pfenex (NYSEAMERICAN PFNX) Insider Trading and Institutional Ownership History
Pfenex (NYSEAMERICAN PFNX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/12/2017||Jason Grenfell-Gardner||Director||Buy||10,000||$4.51||$45,100.00||10,000|| |
|5/16/2017||Patricia Lady||Insider||Sell||2,000||$4.78||$9,560.00|| |
|1/6/2017||Signet Healthcare Partners Acc||Major Shareholder||Sell||400||$9.50||$3,800.00|| |
|1/5/2017||Signet Healthcare Partners Acc||Major Shareholder||Sell||7,710||$9.50||$73,245.00|| |
|12/29/2016||Signet Healthcare Partners Acc||Major Shareholder||Sell||24,104||$9.66||$232,844.64|| |
|12/27/2016||Signet Healthcare Partners Acc||Major Shareholder||Sell||104,600||$9.58||$1,002,068.00|| |
|12/22/2016||Signet Healthcare Partners Acc||Major Shareholder||Sell||10,896||$9.61||$104,710.56|| |
|11/21/2016||Patricia Lady||Insider||Sell||2,000||$9.87||$19,740.00||4,800|| |
|11/15/2016||Patrick K. Lucy||Insider||Sell||5,000||$10.04||$50,200.00|| |
|8/18/2016||Patricia Lady||Insider||Sell||2,000||$9.42||$18,840.00|| |
|5/24/2016||Patricia Lady||CAO||Sell||2,000||$6.52||$13,040.00||4,100|| |
|5/24/2016||Patricia Lady||CAO||Sell||2,000||$6.52||$13,040.00||4,100|| |
|12/15/2015||Chemical Co /De/ Dow||Major Shareholder||Sell||600,000||$11.75||$7,050,000.00||2,221,428|| |
|12/3/2015||Patrick K Lucy||Insider||Sell||1,500||$14.15||$21,225.00||105,690|| |
|12/1/2015||Bertrand C. Liang||CEO||Sell||5,000||$14.88||$74,400.00||522,466|| |
|12/1/2015||Henry W Jr. Talbot||VP||Sell||2,000||$15.08||$30,160.00||118,678|| |
|11/18/2015||Patricia Lady||CAO||Sell||2,000||$14.05||$28,100.00||1,400|| |
|11/4/2015||Patrick K. Lucy||insider||Sell||1,500||$17.54||$26,310.00||107,190|| |
|11/2/2015||Bertrand C Liang||CEO||Sell||5,000||$18.01||$90,050.00||527,466|| |
|10/2/2015||Patrick K Lucy||Insider||Sell||1,500||$14.98||$22,470.00||108,690|| |
|10/1/2015||Bertrand C Liang||CEO||Sell||5,000||$14.78||$73,900.00||532,466|| |
|9/3/2015||Patricia Lady||CAO||Sell||2,000||$20.48||$40,960.00||1,400|| |
|9/3/2015||Patrick K Lucy||Insider||Sell||1,500||$20.91||$31,365.00||110,190|| |
|9/1/2015||Bertrand C. Liang||CEO||Sell||5,000||$21.02||$105,100.00||536,980|| |
|7/6/2015||Patrick K Lucy||Insider||Sell||1,500||$19.17||$28,755.00|| |
|7/1/2015||Bertrand C Liang||CEO||Sell||5,000||$19.63||$98,150.00|| |
|6/3/2015||Patrick K Lucy||Insider||Sell||1,500||$20.08||$30,120.00|| |
|6/1/2015||Bertrand C Liang||CEO||Sell||5,000||$18.70||$93,500.00|| |
|5/4/2015||Patrick K Lucy||Insider||Sell||1,500||$13.25||$19,875.00|| |
|5/1/2015||Bertrand C Liang||CEO||Sell||5,000||$13.49||$67,450.00|| |
|4/29/2015||Chemical Co /De/ Dow||Major Shareholder||Sell||2,232,233||$14.57||$32,523,634.81|| |
|4/29/2015||James C Gale||Director||Sell||1,907,767||$14.57||$27,796,165.19|| |
|4/2/2015||Patrick K Lucy||Insider||Sell||1,500||$17.62||$26,430.00|| |
|4/1/2015||Bertrand C Liang||CEO||Sell||5,000||$15.27||$76,350.00|| |
|3/4/2015||Patrick K Lucy||Insider||Sell||1,500||$14.36||$21,540.00|| |
|7/29/2014||Signet Healthcare Partners Acc||Major Shareholder||Sell||380,867||$0.31||$118,068.77|| |
Pfenex (NYSEAMERICAN PFNX) News Headlines
Pfenex (NYSEAMERICAN:PFNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Pfenex (NYSEAMERICAN PFNX) Stock Chart for Wednesday, March, 21, 2018